LONDON, April 10, 2014 /PRNewswire/ --
On Wednesday, April 09, 2014, the
NASDAQ Composite ended at 4,183.90, up 1.72%, the Dow Jones
Industrial Average advanced 1.11% to 16,437.18, and the S&P 500
closed at 1,872.18, up 1.09%. The gains were broad based as eight
out of 10 sectors ended the session in positive. The S&P 500
Health Care Sector Index finished the day at 673.27, up 2.11%,
while the same has declined 2.01% in the last one month.
Investor-Edge has initiated coverage on the following equities:
Mylan Inc. (NASDAQ: MYL), Actavis PLC (NYSE: ACT), Hospira Inc.
(NYSE: HSP) and The Medicines Co. (NASDAQ: MDCO). Free technical
research on MYL, ACT, HSP and MDCO can be downloaded upon signing
up at:
http://www.investor-edge.com/1000-register
Mylan Inc.'s stock gained 1.95% on Wednesday, closing the day at
$48.57. A total of 12.16 million
shares were traded as compared with its three months average volume
of 5.27 million shares. The company's shares oscillated between
$46.48 and $48.76 during the trading
session. Shares in Mylan Inc. have lost 11.47% in the last one
month, while the same has surged 7.69% in the previous three months
and 11.91% on YTD basis. The stock is trading above its 200-day
moving average. Mylan Inc.'s 50-day moving average of $49.96 is above its 200-day moving average of
$41.48. Furthermore, the company's
stock is trading at a PE ratio of 26.31 and has a Relative Strength
Index (RSI) of 38.71. Sign up today to read free research on MYL
at:
http://www.investor-edge.com/1000-MYL-10Apr2014.pdf
Actavis PLC's stock witnessed a trading volume of 3.80 million
shares on Wednesday, which is above its three months average volume
of 2.73 million shares. The stock ended the day at $201.86, up 5.64%, after trading between
$194.02 and $201.95. Actavis plc.'s
shares have gained 0.27% in the past three trading sessions, 12.18%
in the previous three months, and 20.15% on YTD basis. The stock is
trading above its 200-day moving average. Actavis PLC's 50-day
moving average of $205.15 is above
its 200-day moving average of $162.21. Additionally, shares of the company are
trading at a PE ratio of 58.42 and have an RSI of 31.57. Sign up
today to read free research on ACT at:
http://www.investor-edge.com/1000-ACT-10Apr2014.pdf
On Wednesday, Hospira Inc.'s stock advanced 1.59% finishing the
session at $44.21. The stock recorded
a trading volume of 1.18 million shares which is below its three
months average volume of 1.36 million shares. The company's shares
fluctuated between $43.27 and $44.36
during the session. Hospira Inc.'s shares have gone up 1.98% in the
last one month, 5.39% in the previous three months, and 7.10% on
YTD basis. The stock is trading above its 50-day and 200-day moving
averages. Hospira Inc.'s 50-day moving average of $43.09 is above its 200-day moving average of
$40.93. Moreover, shares of the
company are trading at a PE ratio of 28.39 and have an RSI of
53.90. Sign up today to read free research on HSP at:
http://www.investor-edge.com/1000-HSP-10Apr2014.pdf
The Medicines Co.'s stock recorded a trading volume of 1.38 million
shares on Wednesday, as compared with its three month average
volume of 1.17 million shares. The stock ended the session at
$26.21, up 4.84% after vacillating
between $25.00 and $26.40. The
Medicines Co.'s shares have lost 12.25% in the last one month and
32.13% on YTD basis. The stock is trading below its 50-day and
200-day moving averages. The Medicines Co.'s 200-day moving average
of $33.25 is above its 50-day moving
average of $30.28. Further, the
company's shares are trading at a PE ratio of 44.09 and have an RSI
of 33.11. Sign up today to read free research on MDCO at:
http://www.investor-edge.com/1000-MDCO-10Apr2014.pdf
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a
best efforts basis and reviewed by Namrata
Maheshwari, a CFA charterholder. However, we are only human
and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
3. This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at
compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage
on your company? Send us a full investors' package to research [at]
http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis.
This document, article or report is prepared and authored by
Investor-edge. An outsourced research services provider represented
by Namrata Maheshwari, CFA, has only
reviewed the information provided by Investor-edge in this article
or report according to the Procedures outlined by Investor-edge.
Investor-edge is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the
articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or
otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Investor-edge
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Investor-edge expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Investor-edge does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Investor-Edge